[A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14].

Mednet Member

Medical Oncology · Sediman Cancer Center/University Hospitals of Cleveland Case Medical Center

This is a very thoughtful question. The assumption is that the patient has no evidence on conventional imaging by (CT/Bone scan) and BCR with rapidly doubling PSA after both prostatectomy and adjuvant XRT. The biology of these patients remains concerning and although STAMPEDE would include these typ...